Atopic Dermatitis: What's New in Targeted Therapies

The treatment landscape for moderate-to-severe atopic dermatitis has shifted rapidly from broad immunosuppression to precision approaches aimed at specific drivers of type 2 inflammation and itch. This session reviews the latest developments, including biologics targeting IL-4/IL-13, IL-13, IL-31, and OX40/OX40L pathways, as well as oral and topical JAK inhibitors. Faculty will compare efficacy, safety, and long-term data, discuss how to select therapy for different patient phenotypes and comorbidities, and address practical considerations such as monitoring, access, and treatment sequencing.